My idea is simply that the FDA will be under enormous pressure to expedite potential CV treatments. So, they’re not going to be looking for excuses to delay approval the way they seem to have been with HIV. But approval for CV implies approval for HIV because it is the same process. That increases the likelihood — and maybe even the pace — of HIV approval.